SavedAdd your journal

Journals / Gülhane Tıp Dergisi / 2011 / Cilt: 53 - Sayı: 4

Cytotoxic effect of docetaxel on multiple myeloma cell lines (RPMI- 8226) as a chemotherapotic agent

Kemoterapötik ajan olarak dosetaksel’in multipl miyelom hücre hattı (RPMI-8226) üzerindeki sitotoksik etkisi

Zehra Dilşad ÇOBAN
Ferit AVCU
Ali Uğur URAL
Mesut AKYOL
ŞEFİK GÜRAN
Pages
258–263
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However further animal experiments are needed for the more efficient use of docetaxel in the treatment of multiple myeloma.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Docetaxel that causes microtubule stabilization during mitotic spindle organizing in cell and forces the cell to go apopitosis is a widely used drug in breast, prostate and bladder cancers.
📊
Key Findings & Data:Cytotoxic effect of docetaxel which has been used in the treatment of many other cancers on multiple myeloma cell line (RPMI- ATTC No: CCL-155) was investigated with different drug concentrations.
💡
Conclusion & Impact:However further animal experiments are needed for the more efficient use of docetaxel in the treatment of multiple myeloma.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Docetaxel that causes microtubule stabilization during mitotic spindle organizing in cell and forces the cell to go apopitosis is a widely used drug in breast, prostate and bladder cancers. Cytotoxic effect of docetaxel which has been used in the treatment of many other cancers on multiple myeloma cell line (RPMI- ATTC No: CCL-155) was investigated with different drug concentrations. Metastatic breast cancer [MCF-7 (human breast cancer) ATCC No: HTB-22] (human breast cancer) cell line was used as the control group. Cytotoxic effects occurring with increasing docetaxel concentrations in cell cultures of RPMI-8226 and MCF 7 cell lines were evaluated by XTT assay. Cytotoxic effect caused by docetaxel was lower in MCF-7 (human breast cancer) cell lines of the control group. However cytotoxic effect with increasing docetaxel concentrations in RPMI-8226 (human multiplee myeloma) cell lines was demonstrated. Data demonstrate that docetaxel with a concentration of 50 μmol reaches a lethal dose on RPMI-8226 cell lines. Low cytotoxic effect of docetaxel in the control group is only explained by the metastatic character of breast cancer cell line. Efficient cytotoxic effect of docetaxel in multiple myeloma cell line suggests that this drug may be used in the treatment of this disease. However further animal experiments are needed for the more efficient use of docetaxel in the treatment of multiple myeloma.

Özet

Hücrede mitotik iğciğin oluşum aşamasında mikrotübül stabilizasyonuna neden olarak hücre bölünmesini durdurup hücrenin apopitozise gidişini sağlayan dosetaksel meme, prostat ve mesane kanserinde sık kullanılan bir ilaçtır. Bu çalışmada multipl miyelom hücre hattında [RPMI-8226 (“Human multiplee myeloma”) ATTC No: CCL-155] başka birçok kanserin tedavisinde ilaç olarak kullanılan dosetaksel ile ortaya çıkabilecek sitotoksik etki farklı dosetaksel konsantrasyonları kullanılarak incelenmiştir. Kontrol grubu olarak metastatik meme kanseri hücre hattı [MCF-7 (“human breast cancer”) ATCC No: HTB-22] kullanılmıştır. RPMI-8226 ve MCF 7 hücre hatlarında hücre kültüründe artan dosetaksel konsantrasyonlarında oluşan sitotoksik etkiler XTT uygulaması ile değerlendirilmiştir. Kontrol grubunda yer alan MCF-7 (“Human breast cancer”) hücrelerinde dosetakselin oluşturduğu sitotoksik etki az olarak bulunmuştur. Buna karşın RPMI-8226 (“Human multiplee myeloma”) hücre hattında dosetakselin artan konsantrasyonlarında oluşturduğu sitotoksik etki ortaya konmuştur. Veriler dosetakselin 50 μmol konsantrasyonda RPMI-8226 hücreleri üzerinde letal doza eriştiğini göstermiştir. Kontrol grubunda dosetakselin etkinliğinin düşük olmasının tek sebebi olarak meme kanseri hücre hattının metastatik karakterde olması değerlendirilmiştir. Dosetakselin multipl miyelom hücre hattında etkin sitotoksik etkisi bu ilacın multipl miyelom tedavisinde kullanılabileceğini düşündürmektedir. Ancak ilacın multipl miyeloma tedavisinde daha etkin olarak kullanımı için ileri hayvan deneylerine gereksinim vardır.

🔖

Cite This Article

ÇOBAN, Z. D., AVCU, F., URAL, A. U., AKYOL, M., GÜRAN, Ş. (2011). Cytotoxic effect of docetaxel on multiple myeloma cell lines (RPMI- 8226) as a chemotherapotic agent. Gülhane Tıp Dergisi, Cilt: 53 - Sayı: 4, 258–263. https://ajindex.com/articles/226114

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351: 1860-1873
  2. Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiplee myeloma. Nat Rev Cancer 2002; 2: 927-937
  3. Hervé AL, Florence M, Philippe M, et al. Molecular heterogeneity of multiplee myeloma: pathogenesis, prognosis, and therapeutic implications. J Clin Oncol 2011; 29: 1893-1897
  4. Greipp PR, Trendle MC, Leong T, et al. Is flow cytometric DNA content hypodiploidy prognostic in multiplee myeloma? Leuk Lymphoma 1999; 35: 83-89
  5. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364: 1046-1060
  6. Morse DL, Gray H, Payne CM, Gillies RJ. Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Mol Cancer Ther 2005; 4: 1495-1504
  7. Lyseng-Williamson KA, Fenton C. Docetaxel: a review of its use in metastatic breast cancer. Drugs 2005; 65: 2513-2531
  8. Karampeazis A, Vamvakas L, Agelidou A, et al. Docetaxel vs. vinorelbine in elderly patients with advanced nonsmall- cell lung cancer: A Hellenic Oncology Research Group Randomized Phase III Study. Clin Lung Cancer 2011; 12: 155-160
  9. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisone in the treatment of multiplee myeloma: an overview of published trials. J Clin Oncol 1992; 10: 334-342
  10. Scudiero DA, Shoemaker RH, Paull KD, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988; 48: 4827-4833
  11. Donmez Y, Gunduz U. Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells. Biomed Pharmacother 2011; 65: 85-89
  12. Mutlu PK, Baran Y, Ural AU, et al. Effect of cobalt-60 (gamma radiation) on multidrug resistant multiplee myeloma cell lines. Cell Biol Int 2011; 35: 721-725
  13. Karabulut B, Erten C, Gul MK. Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells. Cell Biol Int 2009; 33: 239-346
  14. Morgan C, Lewis PD, Jones RM. The in vitro antitumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer. Acta Oncol 2007; 46: 669-677
  15. Fury MG, Pfister DG. Current recommendations for systemic therapy of recurrent and/or metastatic head and neck squamous cell cancer. J Natl Compr Canc Netw